Aphranel Welcomes European Physicians to China for Clinical Exchange Program

Aphranel®, the regenerative aesthetics brand of MOYOM Biotech, launched a week-long clinical exchange program titled 'The Norns' Weave,' bringing European physicians to China for clinical observation and discussion. The initiative is designed to immerse European doctors in Chinese clinical expertise and injection techniques, exploring how these methods might inform practices in Europe.

According to the reported announcement, the delegation—including Dr. Tiago Guimarães and Aphranel’s European medical and commercial team—visited multiple Chinese cities. Stops included the Yestar Medical Aesthetic Hospital and Huamei Zixin Medical Aesthetic Hospital in Guangzhou; Shenzhen Fanyan Aesthetics and Shenzhen Boai Shuguang Hospital in Shenzhen; REAL Medical Aesthetic in Shanghai; and Estee Ryan and JollyHue in Hangzhou.

Program Highlights and Clinical Focus

• Immersion and Observation: Participants engaged in facial aesthetic evaluations, clinical case discussions, and live injection demonstrations.
• Anatomical Discussions: Physicians examined regional differences in ethnicity, facial anatomy, and aesthetic preferences.
• CaHA Biostructuring: Discussions covered the use of Aphranel’s MagiCCrystal CaHA filler at various tissue depths, balancing deep periosteal structural support with superficial tissue quality improvements.

Background and Future Outlook

Built on over 12 years of research and development, Aphranel® expanded its international presence following its NMPA class III approval in China in 2025 and EU MDR certification in 2026. The brand reports more than 620 partner aesthetic clinics, over 700 certified physicians, and over 200,000 syringes utilized in China within roughly a year of its launch.

MOYOM Biotech plans to expand 'The Norns' Weave' through future European academic exchanges, expert-to-expert (E2E) collaborations, and ongoing clinical evidence development. Observers can verify the original announcement through PR Newswire and MOYOM Biotech's official corporate communications.